Pharmaceuticals, Biotechnology and Life Sciences
IDEA, who have supported 8 of the 15 biggest biopharmaceutical launches in the past 3 years, will partner with Amarantus in a novel royalty-split model, in a virtual Chief Commercial Officer partnership, to run for five years, designed to provide multi-year commercial strategy to the Amarantus portfolio of companies, with royalties paid to IDEA after monetisation.
Ipsen has presented results of Dysport and botulinum toxins pipeline, from basic science to clinical phases, and patients and caregivers surveys, highlighting differentiation of Dysport in the treatment of spasticity and movement disorders.
ValiRx’s published study of VAL401, a single dose in an open-label trial of late-stage cancer patients, provide support for future studies of VAL401 as a cancer treatment, as the Cmaxdemonstrates sufficient exposure to reach the concentrations seen during preclinical anticancer testing, yet the overall exposure to the active moiety supports the use of the safety and tolerability data from conventional risperidone during future clinical trials.
Blue Water Vaccines, a privately held company, will complete its fund-raising of $15 million to support the flu vaccine program, after agreeing with the University of Oxford, without disclosing terms of the agreement, providing Blue Water Vaccines the option to exclusively license a novel and potentially revolutionary universal influenza vaccine.
Solasia Pharma and PledPharma, have reached an important milestone, triggering €4,78 million payment from Solasia to PledPharma, in Phase III program for drug candidate PledOx in Japan, as the first human has been included in trial.
Corvus Pharmaceuticals’s study of its investigational small molecule T-cell signaling pathway inhibitorresults, indicated that orally-administered CPI-818 produced tumor regression in three of three companion dogs with spontaneous, naturally occurring T-cell lymphomas, without significant toxicity.
The a biotechnology maker of novel oncology and drug-delivery therapies, Halozyme Therapeutics, expects three Enhanze programs to be in phase 3 studies and to have nine active phase 1 programs in addition to its three currently marketed products, by the end of 2019, the company said in an update.
Pharmaceutics International, Contract Development and Manufacturing Organization (CDMO) headquartered in Hunt Valley, Maryland, will produce Bretylium Tosylate for Academic Pharmaceuticals, as it received FDA approval of Bretylium Tosylate Injection USP.
This first IRRAflow patient treatment in the US was performed at the University of California – Irvine (UCI) Medical Center, located in Orange, California, treating a patient suffering from a chronic subdural hematoma that formed after a recent fall.
BerGenBio started testing has started testing anti-AXL therapeutic monoclonal antibody BGB149 with healthy volunteers in its fully own Phase I clinical trial.